The development of drug delivery and imaging tools is a major challenge in human health, in particular in cancer pathologies. This work describes the optimization of a protein nanocontainer, belonging to the lectin protein family, for its use in epithelial cancer diagnosis and treatment. Indeed, it specifically targets a glycosidic marker, the T antigen, which is known to be characteristic of epithelial cancers. Its quaternary structure reveals a large hydrated inner cavity able to transport small therapeutic molecules. Optimization of the nanocontainer by site directed mutagenesis allowed controlling loading and release of confined drugs. Doxorubicin confinement was followed, both theoretically and experimentally, and provided a proof of concept for the use of this nanocontainer as a vectorization system. In OVCAR-3 cells, a human ovarian adenocarcinoma cell line that expresses the T antigen, the drug was observed to be delivered inside late endosomes/lysosomes. These results show that this new type of vectorization and imaging device opens new exciting perspectives in nano-theranostic approaches.

Download full-text PDF

Source
http://dx.doi.org/10.1039/c8nr10249jDOI Listing

Publication Analysis

Top Keywords

protein nanocontainer
8
epithelial cancers
8
nanocontainer targeting
4
targeting epithelial
4
cancers rational
4
rational engineering
4
engineering biochemical
4
biochemical characterization
4
characterization drug
4
drug loading
4

Similar Publications

SARS-CoV-2, the cause of COVID-19, primarily targets lung tissue, leading to pneumonia and lung injury. The spike protein of this virus binds to the common receptor on susceptible tissues and cells called the angiotensin-converting enzyme-2 (ACE2) of the angiotensin (ANG) system. In this study, we produced chimeric Macrobrachium rosenbergii nodavirus virus-like particles, presenting a short peptide ligand (ACE2tp), based on angiotensin-II (ANG II), on their outer surfaces to allow them to specifically bind to ACE2-overexpressing cells called ACE2tp-MrNV-VLPs.

View Article and Find Full Text PDF

Viral capsid assembly and the design of capsid-based nanocontainers critically depend on understanding the shapes and interfaces of constituent protein subunits. However, a comprehensive framework for characterizing these features is still lacking. Here, we introduce a novel approach based on spherical tiling theory that explicitly describes the 2D shapes and interfaces of subunits in icosahedral capsids.

View Article and Find Full Text PDF

Nanobiocatalysis: Approach and Applications in Drug Development and Sensing.

Crit Rev Ther Drug Carrier Syst

September 2024

Associate Professor of Pharmaceutics, Faculty of Health and Allied Sciences, Amity University Noida India, Pharmaceutics Domain, Uttar Pradesh, India; Member, Indian National Young Academy of Sciences (INYAS), INSA, New Delhi, India.

Enzymes play a pivotal role in the human body, but their potential is not limited to just that. Scientists have successfully modified these enzymes as nanobiocatalysts or nanozymes for industrial or commercial use, either in the food, medicine, biotech or even textile industries. These nanobiocatalysts and nanozymes offer several advantages over enzymes, like better stability, improved shelf-life, increased percentage yield, and reuse potential, which is very difficult with normal enzymes.

View Article and Find Full Text PDF
Article Synopsis
  • - Virus-like particles (VLPs), particularly the P22 VLP, are effective nanocarriers for delivering drugs, proteins, and vaccines due to their ability to be modified for enhanced cell targeting and penetration.
  • - The study examined the impact of arginine-rich cell-penetrating peptides (CPPs) TAT and 8R on the transport efficiency and tissue distribution of P22 VLPs, finding that both significantly improved cellular uptake and tissue retention.
  • - Results showed that TAT was more effective for lung tissue distribution 24 hours post-injection, while 8R was better for brain accumulation, highlighting TAT's superiority in enhancing delivery effectiveness of P22 VLPs.
View Article and Find Full Text PDF

Gramicidin S (GS), one of the first discovered antimicrobial peptides, still shows strong antibiotic activity after decades of clinical use, with no evidence of resistance. The relatively high hemolytic activity and narrow therapeutic window of GS limit its use in topical applications. Encapsulation and targeted delivery may be the way to develop the internal administration of this drug.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!